Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.18
GB's Cash to Debt is ranked lower than
57% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. GB: 0.18 )
GB' s 10-Year Cash to Debt Range
Min: 0.03   Max: 0.84
Current: 0.18

0.03
0.84
Equity to Asset 0.61
GB's Equity to Asset is ranked higher than
64% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. GB: 0.61 )
GB' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.75
Current: 0.61

0.25
0.75
Interest Coverage 5.45
GB's Interest Coverage is ranked lower than
56% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. GB: 5.45 )
GB' s 10-Year Interest Coverage Range
Min: 0.05   Max: 9.31
Current: 5.45

0.05
9.31
F-Score: 8
Z-Score: 3.42
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 9.24
GB's Operating margin (%) is ranked higher than
78% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. GB: 9.24 )
GB' s 10-Year Operating margin (%) Range
Min: 0.2   Max: 17.66
Current: 9.24

0.2
17.66
Net-margin (%) 5.46
GB's Net-margin (%) is ranked higher than
74% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. GB: 5.46 )
GB' s 10-Year Net-margin (%) Range
Min: -2.87   Max: 10.76
Current: 5.46

-2.87
10.76
ROE (%) 6.69
GB's ROE (%) is ranked higher than
73% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. GB: 6.69 )
GB' s 10-Year ROE (%) Range
Min: -4.9   Max: 9.9
Current: 6.69

-4.9
9.9
ROA (%) 4.07
GB's ROA (%) is ranked higher than
73% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. GB: 4.07 )
GB' s 10-Year ROA (%) Range
Min: -1.2   Max: 5.31
Current: 4.07

-1.2
5.31
ROC (Joel Greenblatt) (%) 20.38
GB's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. GB: 20.38 )
GB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.39   Max: 36.73
Current: 20.38

0.39
36.73
Revenue Growth (%) 5.40
GB's Revenue Growth (%) is ranked higher than
71% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. GB: 5.40 )
GB' s 10-Year Revenue Growth (%) Range
Min: 0.2   Max: 30.3
Current: 5.4

0.2
30.3
EBITDA Growth (%) -4.50
GB's EBITDA Growth (%) is ranked higher than
73% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. GB: -4.50 )
GB' s 10-Year EBITDA Growth (%) Range
Min: -7.6   Max: 30.6
Current: -4.5

-7.6
30.6
EPS Growth (%) 1.00
GB's EPS Growth (%) is ranked higher than
77% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. GB: 1.00 )
GB' s 10-Year EPS Growth (%) Range
Min: -20   Max: 146.6
Current: 1

-20
146.6
» GB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

GB Guru Trades in Q1 2013

Chuck Royce 212,100 sh (+12.22%)
Diamond Hill Capital 606,424 sh (+1.87%)
Paul Tudor Jones Sold Out
Mario Gabelli 314,100 sh (-0.1%)
Jim Simons 9,500 sh (-65.83%)
» More
Q2 2013

GB Guru Trades in Q2 2013

Jim Simons Sold Out
Diamond Hill Capital 590,564 sh (-2.62%)
Mario Gabelli 287,100 sh (-8.6%)
Chuck Royce 178,500 sh (-15.84%)
» More
Q3 2013

GB Guru Trades in Q3 2013

Jim Simons 9,500 sh (New)
Paul Tudor Jones 20,400 sh (New)
Steven Cohen 10,815 sh (New)
Diamond Hill Capital 623,135 sh (+5.52%)
Mario Gabelli 277,600 sh (-3.31%)
Chuck Royce 82,000 sh (-54.06%)
» More
Q4 2013

GB Guru Trades in Q4 2013

Steven Cohen 201,440 sh (+1762.6%)
Jim Simons 23,100 sh (+143.16%)
Chuck Royce 83,000 sh (+1.22%)
Paul Tudor Jones Sold Out
Diamond Hill Capital 614,570 sh (-1.37%)
Mario Gabelli 250,600 sh (-9.73%)
» More
» Details

Insider Trades

Latest Guru Trades with GB

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2012-06-30 Sold Out 0.09%$20.5 - $24.73 $ 47.68115%0
Joel Greenblatt 2012-03-31 Reduce -22.75%0.03%$21.51 - $25.49 $ 47.68114%41455
Mario Gabelli 2012-03-31 Add 53.3%0.02%$21.51 - $25.49 $ 47.68114%320400
Joel Greenblatt 2011-12-31 Add 21.58%0.02%$18.86 - $22.74 $ 47.68127%53665
Joel Greenblatt 2011-09-30 Add 49.86%0.05%$19.19 - $28.2 $ 47.68107%44139
Joel Greenblatt 2011-06-30 Reduce -22.91%0.07%$25.32 - $28.95 $ 47.6877%29453
Mario Gabelli 2011-06-30 Add 40.27%0.01%$25.32 - $28.95 $ 47.6877%209000
Joel Greenblatt 2011-03-31 Add 97.46%0.15%$22.94 - $26.33 $ 47.6895%38207
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.30
GB's P/E(ttm) is ranked higher than
56% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. GB: 33.30 )
GB' s 10-Year P/E(ttm) Range
Min: 11.04   Max: 575.08
Current: 33.3

11.04
575.08
P/B 2.10
GB's P/B is ranked higher than
73% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. GB: 2.10 )
GB' s 10-Year P/B Range
Min: 0.97   Max: 3.95
Current: 2.1

0.97
3.95
P/S 1.82
GB's P/S is ranked higher than
68% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. GB: 1.82 )
GB' s 10-Year P/S Range
Min: 0.78   Max: 4.47
Current: 1.82

0.78
4.47
PFCF 33.20
GB's PFCF is ranked higher than
52% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. GB: 33.20 )
GB' s 10-Year PFCF Range
Min: 6.12   Max: 169.91
Current: 33.2

6.12
169.91
EV-to-EBIT 21.70
GB's EV-to-EBIT is ranked higher than
62% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. GB: 21.70 )
GB' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 3207.3
Current: 21.7

8.3
3207.3
PEG 4.10
GB's PEG is ranked higher than
61% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. GB: 4.10 )
GB' s 10-Year PEG Range
Min: 0.71   Max: 920.69
Current: 4.1

0.71
920.69
Shiller P/E 64.80
GB's Shiller P/E is ranked lower than
57% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 26.95 vs. GB: 64.80 )
GB' s 10-Year Shiller P/E Range
Min: 22.96   Max: 64.8
Current: 64.8

22.96
64.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.60
GB's Price/Tangible Book is ranked lower than
75% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. GB: 11.60 )
GB' s 10-Year Price/Tangible Book Range
Min: 6.71   Max: 63.14
Current: 11.6

6.71
63.14
Price/DCF (Projected) 1.50
GB's Price/DCF (Projected) is ranked higher than
75% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. GB: 1.50 )
GB' s 10-Year Price/DCF (Projected) Range
Min: 0.55   Max: 1.66
Current: 1.5

0.55
1.66
Price/Median PS Value 1.40
GB's Price/Median PS Value is ranked lower than
55% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. GB: 1.40 )
GB' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 4.02
Current: 1.4

0.65
4.02
Price/Graham Number 4.10
GB's Price/Graham Number is ranked lower than
65% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. GB: 4.10 )
GB' s 10-Year Price/Graham Number Range
Min: 3.15   Max: 19.76
Current: 4.1

3.15
19.76
Earnings Yield (Greenblatt) 4.60
GB's Earnings Yield (Greenblatt) is ranked higher than
70% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. GB: 4.60 )
GB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 12
Current: 4.6

0.1
12
Forward Rate of Return (Yacktman) 5.39
GB's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. GB: 5.39 )
GB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 25.5
Current: 5.39

3.1
25.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:WGB.Germany
Greatbatch, Inc is a Delaware corporation was incorporated in 1997. The Company is a developer and manufacturer of critical products used in medical devices for the cardiac rhythm management, neuromodulation, vascular, orthopedic and interventional radiology markets. Its two reportable segments are Greatbatch Medical and Electrochem Solution. The Greatbatch Medical segment designs and manufactures medical devices and components primarily for the Cardiac Rhythm Management, Neuromodulation, Vascular Access and Orthopaedic markets. Additionally, Greatbatch Medical offers assembly and design engineering services for products that incorporate Greatbatch Medical components. Greatbatch Medical also offers its customers complete medical devices including design, development, manufacturing, regulatory submission and supporting worldwide distribution. Electrochem provides technology solutions where safety, reliability, quality and durability are critical. Electrochem's customized primary (non-rechargeable) and secondary (rechargeable) battery solutions are used in markets such as energy, portable medical, military, environmental and more. Electrochem's product lines cover a number of highly-customized battery-powered applications in remote and demanding environments, including down hole drilling tools, military communication devices, automated external defibrillators, oceanographic buoys and more. Electrochem's primary and secondary power solutions and wireless sensing systems are used in markets where failure is not an option. Electrochem's product designs incorporate protective circuitry, glass-to-metal hermetic seals, fuses and diodes to help ensure safe, durable and reliable power as devices are subjected to these harsh conditions. Its secondary power solutions comprise a number of chemistries including lithium, nickel and lead acid. These solutions also provide value-adds that complement each power source, including engineering design expertise, advanced electronics, smart charging and battery management systems, to ensure each solution is ready to perform in mission critical and life-saving applications. Products from its Greatbatch Medical business are sold directly to its customers. In its Electrochem business, the Company utilizes a combination of direct and indirect sales methods, depending on the particular product. Greatbatch Medical customers include large multi-national OEMs and their affiliated subsidiaries such as, Biotronik, Boston Scientific, Johnson & Johnson, Medtronic, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker and Zimmer. Electrochem customers include General Electric, Halliburton Company, Scripps Institution of Oceanography, Thales, Weatherford International and Zoll Medical Corp. The main raw materials used in the Company's business include lithium, iodine, tantalum, platinum, ruthenium, gallium trichloride, tantalum pellets, vanadium pentoxide, iridium, and titanium. Existing and potential competitors i

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide